http://142-54-23-223.fusionmedialtd.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 18 Aug 2026 18:12:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://142-54-23-223.fusionmedialtd.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++LifeMD%2C+Inc.++++++++++++++For%3A+Aug+11++Filed+by%3A+LAROVERE+JOAN/26945742.html si-local-file:///var/storage/secattach/20260818/26945742.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++LifeMD%2C+Inc.++++++++++++++For%3A+Aug+11++Filed+by%3A+LAROVERE+JOAN/26945742.html Tue, 18 Aug 2026 18:12:00 -0400 LFMD O.09946953 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++LifeMD%2C+Inc.++++++++++++++For%3A+Aug+11++Filed+by%3A+LAROVERE+JOAN/26945742.html si-local-file:///var/storage/secattach/20260818/26945742.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++LifeMD%2C+Inc.++++++++++++++For%3A+Aug+11++Filed+by%3A+LAROVERE+JOAN/26945742.html Tue, 18 Aug 2026 18:12:00 -0400 LFMD O.09946953 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++LifeMD%2C+Inc.++++++++++++++For%3A+May+04++Filed+by%3A+Strawn+John+R+Jr/26945117.html si-local-file:///var/storage/secattach/20260818/26945117.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++LifeMD%2C+Inc.++++++++++++++For%3A+May+04++Filed+by%3A+Strawn+John+R+Jr/26945117.html Tue, 18 Aug 2026 16:51:00 -0400 LFMD O.09946953 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++LifeMD%2C+Inc.++++++++++++++For%3A+May+04++Filed+by%3A+Strawn+John+R+Jr/26945117.html si-local-file:///var/storage/secattach/20260818/26945117.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++LifeMD%2C+Inc.++++++++++++++For%3A+May+04++Filed+by%3A+Strawn+John+R+Jr/26945117.html Tue, 18 Aug 2026 16:51:00 -0400 LFMD O.09946953 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++LifeMD%2C+Inc.++++++++++++++For%3A+Aug+11++Filed+by%3A+DiTrolio+Joseph/26923243.html si-local-file:///var/storage/secattach/20260813/26923243.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++LifeMD%2C+Inc.++++++++++++++For%3A+Aug+11++Filed+by%3A+DiTrolio+Joseph/26923243.html Thu, 13 Aug 2026 21:25:00 -0400 LFMD O.09946953 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++LifeMD%2C+Inc.++++++++++++++For%3A+Aug+11++Filed+by%3A+DiTrolio+Joseph/26923243.html si-local-file:///var/storage/secattach/20260813/26923243.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++LifeMD%2C+Inc.++++++++++++++For%3A+Aug+11++Filed+by%3A+DiTrolio+Joseph/26923243.html Thu, 13 Aug 2026 21:25:00 -0400 LFMD O.09946953 http://www.streetinsider.com/SEC+Filings/Form++4A++++++++LifeMD%2C+Inc.++++++++++++++For%3A+Dec+02++Filed+by%3A+Simon+Roberto/26923010.html si-local-file:///var/storage/secattach/20260813/26923010.html http://www.streetinsider.com/SEC+Filings/Form++4A++++++++LifeMD%2C+Inc.++++++++++++++For%3A+Dec+02++Filed+by%3A+Simon+Roberto/26923010.html Thu, 13 Aug 2026 18:07:00 -0400 LFMD O.09946953 http://www.streetinsider.com/SEC+Filings/Form++4A++++++++LifeMD%2C+Inc.++++++++++++++For%3A+Dec+02++Filed+by%3A+Simon+Roberto/26923010.html si-local-file:///var/storage/secattach/20260813/26923010.html http://www.streetinsider.com/SEC+Filings/Form++4A++++++++LifeMD%2C+Inc.++++++++++++++For%3A+Dec+02++Filed+by%3A+Simon+Roberto/26923010.html Thu, 13 Aug 2026 18:07:00 -0400 LFMD O.09946953 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++LifeMD%2C+Inc.++++++++++++++For%3A+May+04++Filed+by%3A+Simon+Roberto/26923003.html si-local-file:///var/storage/secattach/20260813/26923003.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++LifeMD%2C+Inc.++++++++++++++For%3A+May+04++Filed+by%3A+Simon+Roberto/26923003.html Thu, 13 Aug 2026 18:03:00 -0400 LFMD O.09946953 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++LifeMD%2C+Inc.++++++++++++++For%3A+May+04++Filed+by%3A+Simon+Roberto/26923003.html si-local-file:///var/storage/secattach/20260813/26923003.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++LifeMD%2C+Inc.++++++++++++++For%3A+May+04++Filed+by%3A+Simon+Roberto/26923003.html Thu, 13 Aug 2026 18:03:00 -0400 LFMD O.09946953 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++LifeMD%2C+Inc.++++++++++++++For%3A+Aug+11++Filed+by%3A+MACRAE+CALUM+ARCHIBALD/26922971.html si-local-file:///var/storage/secattach/20260813/26922971.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++LifeMD%2C+Inc.++++++++++++++For%3A+Aug+11++Filed+by%3A+MACRAE+CALUM+ARCHIBALD/26922971.html Thu, 13 Aug 2026 17:49:00 -0400 LFMD O.09946953 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++LifeMD%2C+Inc.++++++++++++++For%3A+Aug+11++Filed+by%3A+MACRAE+CALUM+ARCHIBALD/26922971.html si-local-file:///var/storage/secattach/20260813/26922971.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++LifeMD%2C+Inc.++++++++++++++For%3A+Aug+11++Filed+by%3A+MACRAE+CALUM+ARCHIBALD/26922971.html Thu, 13 Aug 2026 17:49:00 -0400 LFMD O.09946953 http://www.streetinsider.com/Analyst+PT+Change/LifeMD+Inc+%28LFMD%29+PT+Lowered+to+%248+at+B.Riley/26880544.html B.Riley analyst Kyle Bauser lowered the price target on LifeMD Inc (NASDAQ: LFMD) to $8.00 (from $10.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/LifeMD+Inc+%28LFMD%29+PT+Lowered+to+%248+at+B.Riley/26880544.html Thu, 06 Aug 2026 09:12:04 -0400 LFMD http://www.streetinsider.com/Analyst+PT+Change/LifeMD+Inc+%28LFMD%29+PT+Lowered+to+%247+at+Mizuho/26878108.html Mizuho analyst Steven Valiquette lowered the price target on LifeMD Inc (NASDAQ: LFMD) to $7.00 (from $8.00) while maintaining a Outperform rating. http://www.streetinsider.com/Analyst+PT+Change/LifeMD+Inc+%28LFMD%29+PT+Lowered+to+%247+at+Mizuho/26878108.html Thu, 06 Aug 2026 06:52:05 -0400 LFMD http://www.streetinsider.com/Press+Releases/UPDATE+-+LifeMD+Reports+Second+Quarter+2026+Results/26876517.html <p>UPDATE this press release has been updated to remove a duplicate table. </p> <ul><li>Second quarter 2026 revenue of $47.3 million, within the Company’s guidance range of $47 million to $50 million; adjusted EBITDA loss of approximately $3.5 million, improving approximately 21% sequentially.</li><li>Approximately 95% of all new weight management patients now begin treatment with branded GLP-1 therapies; with the guidance provided today, the Company believes it is effectively at the end of its transition away from compounded GLP-1 medications.</li><li>Gross margin expanded approximately 280 basis points versus the second quarter of 2025 to approximately 89%, reflecting lower shipping and fulfillment costs http://www.streetinsider.com/Press+Releases/UPDATE+-+LifeMD+Reports+Second+Quarter+2026+Results/26876517.html Wed, 05 Aug 2026 19:45:00 -0400 A.15159508 A.30035300 LFMD LFMDP O.00649154 O.09946953 O.20947283 http://www.streetinsider.com/Press+Releases/UPDATE+-+LifeMD+Reports+Second+Quarter+2026+Results/26876517.html <p>UPDATE this press release has been updated to remove a duplicate table. </p> <ul><li>Second quarter 2026 revenue of $47.3 million, within the Company’s guidance range of $47 million to $50 million; adjusted EBITDA loss of approximately $3.5 million, improving approximately 21% sequentially.</li><li>Approximately 95% of all new weight management patients now begin treatment with branded GLP-1 therapies; with the guidance provided today, the Company believes it is effectively at the end of its transition away from compounded GLP-1 medications.</li><li>Gross margin expanded approximately 280 basis points versus the second quarter of 2025 to approximately 89%, reflecting lower shipping and fulfillment costs http://www.streetinsider.com/Press+Releases/UPDATE+-+LifeMD+Reports+Second+Quarter+2026+Results/26876517.html Wed, 05 Aug 2026 19:45:00 -0400 A.15159508 A.30035300 LFMD LFMDP O.00649154 O.09946953 O.20947283 http://www.streetinsider.com/Press+Releases/UPDATE+-+LifeMD+Reports+Second+Quarter+2026+Results/26876517.html <p>UPDATE this press release has been updated to remove a duplicate table. </p> <ul><li>Second quarter 2026 revenue of $47.3 million, within the Company’s guidance range of $47 million to $50 million; adjusted EBITDA loss of approximately $3.5 million, improving approximately 21% sequentially.</li><li>Approximately 95% of all new weight management patients now begin treatment with branded GLP-1 therapies; with the guidance provided today, the Company believes it is effectively at the end of its transition away from compounded GLP-1 medications.</li><li>Gross margin expanded approximately 280 basis points versus the second quarter of 2025 to approximately 89%, reflecting lower shipping and fulfillment costs http://www.streetinsider.com/Press+Releases/UPDATE+-+LifeMD+Reports+Second+Quarter+2026+Results/26876517.html Wed, 05 Aug 2026 19:45:00 -0400 A.15159508 A.30035300 LFMD LFMDP O.00649154 O.09946953 O.20947283 http://www.streetinsider.com/Press+Releases/UPDATE+-+LifeMD+Reports+Second+Quarter+2026+Results/26876517.html <p>UPDATE this press release has been updated to remove a duplicate table. </p> <ul><li>Second quarter 2026 revenue of $47.3 million, within the Company’s guidance range of $47 million to $50 million; adjusted EBITDA loss of approximately $3.5 million, improving approximately 21% sequentially.</li><li>Approximately 95% of all new weight management patients now begin treatment with branded GLP-1 therapies; with the guidance provided today, the Company believes it is effectively at the end of its transition away from compounded GLP-1 medications.</li><li>Gross margin expanded approximately 280 basis points versus the second quarter of 2025 to approximately 89%, reflecting lower shipping and fulfillment costs http://www.streetinsider.com/Press+Releases/UPDATE+-+LifeMD+Reports+Second+Quarter+2026+Results/26876517.html Wed, 05 Aug 2026 19:45:00 -0400 A.15159508 A.30035300 LFMD LFMDP O.00649154 O.09946953 O.20947283 http://www.streetinsider.com/Press+Releases/UPDATE+-+LifeMD+Reports+Second+Quarter+2026+Results/26876517.html <p>UPDATE this press release has been updated to remove a duplicate table. </p> <ul><li>Second quarter 2026 revenue of $47.3 million, within the Company’s guidance range of $47 million to $50 million; adjusted EBITDA loss of approximately $3.5 million, improving approximately 21% sequentially.</li><li>Approximately 95% of all new weight management patients now begin treatment with branded GLP-1 therapies; with the guidance provided today, the Company believes it is effectively at the end of its transition away from compounded GLP-1 medications.</li><li>Gross margin expanded approximately 280 basis points versus the second quarter of 2025 to approximately 89%, reflecting lower shipping and fulfillment costs http://www.streetinsider.com/Press+Releases/UPDATE+-+LifeMD+Reports+Second+Quarter+2026+Results/26876517.html Wed, 05 Aug 2026 19:45:00 -0400 A.15159508 A.30035300 LFMD LFMDP O.00649154 O.09946953 O.20947283 http://www.streetinsider.com/Press+Releases/UPDATE+-+LifeMD+Reports+Second+Quarter+2026+Results/26876517.html <p>UPDATE this press release has been updated to remove a duplicate table. </p> <ul><li>Second quarter 2026 revenue of $47.3 million, within the Company’s guidance range of $47 million to $50 million; adjusted EBITDA loss of approximately $3.5 million, improving approximately 21% sequentially.</li><li>Approximately 95% of all new weight management patients now begin treatment with branded GLP-1 therapies; with the guidance provided today, the Company believes it is effectively at the end of its transition away from compounded GLP-1 medications.</li><li>Gross margin expanded approximately 280 basis points versus the second quarter of 2025 to approximately 89%, reflecting lower shipping and fulfillment costs http://www.streetinsider.com/Press+Releases/UPDATE+-+LifeMD+Reports+Second+Quarter+2026+Results/26876517.html Wed, 05 Aug 2026 19:45:00 -0400 A.15159508 A.30035300 LFMD LFMDP O.00649154 O.09946953 O.20947283 http://www.streetinsider.com/Press+Releases/UPDATE+-+LifeMD+Reports+Second+Quarter+2026+Results/26876517.html <p>UPDATE this press release has been updated to remove a duplicate table. </p> <ul><li>Second quarter 2026 revenue of $47.3 million, within the Company’s guidance range of $47 million to $50 million; adjusted EBITDA loss of approximately $3.5 million, improving approximately 21% sequentially.</li><li>Approximately 95% of all new weight management patients now begin treatment with branded GLP-1 therapies; with the guidance provided today, the Company believes it is effectively at the end of its transition away from compounded GLP-1 medications.</li><li>Gross margin expanded approximately 280 basis points versus the second quarter of 2025 to approximately 89%, reflecting lower shipping and fulfillment costs http://www.streetinsider.com/Press+Releases/UPDATE+-+LifeMD+Reports+Second+Quarter+2026+Results/26876517.html Wed, 05 Aug 2026 19:45:00 -0400 A.15159508 A.30035300 LFMD LFMDP O.00649154 O.09946953 O.20947283 http://www.streetinsider.com/Globe+Newswire/UPDATE+-+LifeMD+Reports+Second+Quarter+2026+Results/26876517.html <p>UPDATE this press release has been updated to remove a duplicate table. </p> <ul><li>Second quarter 2026 revenue of $47.3 million, within the Company’s guidance range of $47 million to $50 million; adjusted EBITDA loss of approximately $3.5 million, improving approximately 21% sequentially.</li><li>Approximately 95% of all new weight management patients now begin treatment with branded GLP-1 therapies; with the guidance provided today, the Company believes it is effectively at the end of its transition away from compounded GLP-1 medications.</li><li>Gross margin expanded approximately 280 basis points versus the second quarter of 2025 to approximately 89%, reflecting lower shipping and fulfillment costs http://www.streetinsider.com/Globe+Newswire/UPDATE+-+LifeMD+Reports+Second+Quarter+2026+Results/26876517.html Wed, 05 Aug 2026 19:45:00 -0400 A.15159508 A.30035300 LFMD LFMDP O.00649154 O.09946953 O.20947283 http://www.streetinsider.com/Globe+Newswire/UPDATE+-+LifeMD+Reports+Second+Quarter+2026+Results/26876517.html <p>UPDATE this press release has been updated to remove a duplicate table. </p> <ul><li>Second quarter 2026 revenue of $47.3 million, within the Company’s guidance range of $47 million to $50 million; adjusted EBITDA loss of approximately $3.5 million, improving approximately 21% sequentially.</li><li>Approximately 95% of all new weight management patients now begin treatment with branded GLP-1 therapies; with the guidance provided today, the Company believes it is effectively at the end of its transition away from compounded GLP-1 medications.</li><li>Gross margin expanded approximately 280 basis points versus the second quarter of 2025 to approximately 89%, reflecting lower shipping and fulfillment costs http://www.streetinsider.com/Globe+Newswire/UPDATE+-+LifeMD+Reports+Second+Quarter+2026+Results/26876517.html Wed, 05 Aug 2026 19:45:00 -0400 A.15159508 A.30035300 LFMD LFMDP O.00649154 O.09946953 O.20947283 http://www.streetinsider.com/Globe+Newswire/UPDATE+-+LifeMD+Reports+Second+Quarter+2026+Results/26876517.html <p>UPDATE this press release has been updated to remove a duplicate table. </p> <ul><li>Second quarter 2026 revenue of $47.3 million, within the Company’s guidance range of $47 million to $50 million; adjusted EBITDA loss of approximately $3.5 million, improving approximately 21% sequentially.</li><li>Approximately 95% of all new weight management patients now begin treatment with branded GLP-1 therapies; with the guidance provided today, the Company believes it is effectively at the end of its transition away from compounded GLP-1 medications.</li><li>Gross margin expanded approximately 280 basis points versus the second quarter of 2025 to approximately 89%, reflecting lower shipping and fulfillment costs http://www.streetinsider.com/Globe+Newswire/UPDATE+-+LifeMD+Reports+Second+Quarter+2026+Results/26876517.html Wed, 05 Aug 2026 19:45:00 -0400 A.15159508 A.30035300 LFMD LFMDP O.00649154 O.09946953 O.20947283 http://www.streetinsider.com/Globe+Newswire/UPDATE+-+LifeMD+Reports+Second+Quarter+2026+Results/26876517.html <p>UPDATE this press release has been updated to remove a duplicate table. </p> <ul><li>Second quarter 2026 revenue of $47.3 million, within the Company’s guidance range of $47 million to $50 million; adjusted EBITDA loss of approximately $3.5 million, improving approximately 21% sequentially.</li><li>Approximately 95% of all new weight management patients now begin treatment with branded GLP-1 therapies; with the guidance provided today, the Company believes it is effectively at the end of its transition away from compounded GLP-1 medications.</li><li>Gross margin expanded approximately 280 basis points versus the second quarter of 2025 to approximately 89%, reflecting lower shipping and fulfillment costs http://www.streetinsider.com/Globe+Newswire/UPDATE+-+LifeMD+Reports+Second+Quarter+2026+Results/26876517.html Wed, 05 Aug 2026 19:45:00 -0400 A.15159508 A.30035300 LFMD LFMDP O.00649154 O.09946953 O.20947283